On Thursday, Shares of Rayonier Advanced Materials Inc (NYSE:RYAM), gained 25.31% to $10.00.
Rayonier Advanced Materials, stated net income for the third quarter 2015 of $32 million, and $0.76 diluted earnings per share, contrast to net income of $19 million, and $0.46 diluted earnings per share for the same period in 2014.
Pro forma net income for the third quarter 2015 was $33 million, or $0.78 per share contrast to $22 million or $0.53 per share for the preceding year period. Year-to-date pro forma net income was $60 million, or $1.42 per share, contrast to $80 million, or $1.90 per share, for the preceding year period.
Third Quarter and Year-to-Date Results
Sales of $257 million for the quarter were comparable to third quarter 2014. Sales for the nine months ended September 26, 2015 of $700 million, were also comparable to the preceding year period. As predictable, cellulose specialties prices were down 6 percent and 7 percent from the preceding year three month and nine month periods, respectively, reflecting the results of our 2015 price negotiations. Cellulose specialties sales volumes for the three months were slightly higher and, for the nine months, slightly lower contrast to the preceding year periods. Commodity product sales volumes raised significantly reflecting improved production efficiency and more operating days in 2015.
Pro forma operating income was $60 million for the third quarter, up 28 percent from the preceding year, as stronger cellulose specialties and commodity volumes combined with lower costs more than offset lower cellulose specialties sales prices. Costs were lower due to cost reduction activities and favorable wood, chemical and energy prices. Year-to-date, pro forma operating income was $118 million, down 13 percent from the preceding year period as lower cellulose specialties sales prices and volumes were partially offset by lower costs and higher commodity sales volumes. In addition, the year-to-date 2014 period reflects carve-out accounting treatment for the first six months of the year. As such, the selling and general expenses are not comparable to the stand-alone company’s costs.
Rayonier Advanced Materials Inc. manufactures and sells cellulose specialty products in the United States, China, Japan, Canada, Europe, Latin America, and other Asian countries.
Shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX), inclined 20.62% to $3.51, during its last trading session.
Nymox Pharmaceutical Corporation, stated that long-term randomized cross-over data from the Company’s trial of fexapotide triflutate for low grade localized prostate cancer has shown statistical significance in efficacy contrast to controls. The study results indicate that randomized control subjects who subsequently switched to fexapotide had long-term outcomes significantly superior to control patients who did not change (cross-over) to fexapotide treatment.
These results are the initial 18 month follow-up results for the fexapotide trial for prostate cancer to be stated. The cross-over study arm of NX03-0040 comprised of 35 subjects. Based on biopsy progression the proportion of patients who progressed on biopsy and required biopsy progression-related surgery or radiotherapy in the cross-over group (0%) at 18 months was significantly less than in the control group (p<.03).
The cross-over group patients received randomized fexapotide 15 mg or 2.5 mg in a single treatment targeted toward the positive baseline cancer focus identified in initial positive biopsies. There were no cases in either of the 2 fexapotide dosage level treatment groups with biopsy progression at 18 months (p<.03).
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. It offers NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products; and AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimers disease.
Finally, Shares of Monsanto Company (NYSE:MON), ended its last trade with 1.32% gain, and closed at $93.73.
Monsanto Company, declared that its Board of Directors has designated Friday, Jan. 29, 2016, as the date of the next annual meeting of shareowners.
Monsanto’s annual meeting will be held at the company’s headquarters in suburban St. Louis. Additional meeting details will be comprised in the company’s proxy statement, which will be available in December. The record date for Monsanto’s annual meeting of shareowners is Tuesday, Dec. 1, 2015.
Monsanto Company, together with its auxiliaries, provides agricultural products for farmers worldwide. It operates in two segments, Seeds and Genomics, and Agricultural Productivity. The Seeds and Genomics segment produces row crop seeds, counting corn, soybean, cotton, and canola seeds principally under the DEKALB, Channel, Asgrow, and Deltapine brands; and vegetable seeds comprising of tomato, pepper, melon, cucumber, pumpkin, squash, beans, broccoli, onions, lettuce, and other seeds under the Seminis and De Ruiter brands.